Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20673370 | 0.97 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1LMNACDC25B | |
| SCHEMBL26315892 | 0.96 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1LMNACDC25B | |
| SCHEMBL26315829 | 0.87 | EPHX2 (0.50) | ALDH1A1LMNAKMT2ACYP3A4MEN1 | |
| SCHEMBL17230150 | 0.86 | ALDH1A1 (0.38) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL3963428 | 0.84 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1LMNACDC25B | |
| SCHEMBL27438917 | 0.83 | LMNA (0.47) | ALDH1A1L3MBTL1LMNAKMT2ACYP3A4 | |
| SCHEMBL27438957 | 0.83 | LMNA (0.47) | ALDH1A1L3MBTL1LMNAKMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL28852620 | 0.82 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1LMNACDC25B | |
| SCHEMBL2423126 | 0.82 | HTT (0.59) | L3MBTL1LMNAHTTEPHX2SMN1; SMN2 | |
| SCHEMBL20577215 | 0.81 | LMNA (0.47) | ALDH1A1L3MBTL1LMNAKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4534092-B1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4711459-A2 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260035695-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260022382-A1 | Compositions and Methods for Modulating Complement Factor B Expression | IONIS PHARMACEUTICALS, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12516319-B2 | Compositions and methods for modulating TTR expression | IONIS PHARMACEUTICALS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12509684-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250346899-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12291709-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-119913147-A | Compositions and methods for modulating apolipoprotein C-III expression | IONIS制药公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4534092-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2015042447-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179625-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179629-A2 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035695-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOL1, APOB, PCSK9 | ALDH1A1 3343/4885MAPK1 1980/4885L3MBTL1 3775/4885 |
| US-20260022382-A1 | Compositions and Methods for Modulating Complement Factor B Expression | CFB, CFH, C5 | ALDH1A1 4514/4885MAPK1 778/4885L3MBTL1 57/4885 |
| US-12509684-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, NSUN2 | ALDH1A1 4690/4885MAPK1 3043/4885L3MBTL1 286/4885 |
| US-12291709-B2 | Compositions and methods for modulating apolipoprotein (a) expression | APOB, APOL1, LDLR | ALDH1A1 1781/4885MAPK1 3716/4885L3MBTL1 1288/4885 |
| US-20250346899-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | CSGALNACT1, GALNT1, GALNT6 | ALDH1A1 1877/4885MAPK1 3983/4885L3MBTL1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.